A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization

Objective: To compare stimulation profiles, pregnancy, and live birth rates in poor responders during in vitro fertilization (IVF) cycles using either a gonadotropin-releasing hormone (GnRH) antagonist (cetrorelix) or a GnRH agonist flare protocol (leuprolide). Design: Retrospective chart review. Setting: A university-affiliated lVF program. Patient(s): Women designated as poor responders based on a prior stimulation cycle or baseline follicle-stimulating hormone (FSH) level of > 10 mIU/mL, who needed at least 375 IU of starting daily gonadotropins in the study cycle. Intervention(S): Administration of GnRH agonist flare or GnRH antagonist protocol. Main Outcome Measure(s): Clinical pregnancy rate. live birth rate. Result(s): For 68 GnRH antagonist and 45 GnRH agonist flare cycles, the groups were similar with respect to age (38.8 versus 38.6 years) and basal FSH concentration (8.33 versus 8.65 mIU/mL). No statistically significant differences between the protocol types were noted in peak estradiol levels, amount of gonadotropins used, number of oocytes obtained, or embryos transferred. The pregnancy rates (40% versus 45.2%) and live birth rates (27.7% versus 31.7%) in the GnRH antagonist and flare groups, respectively, were similar. Conclusion(s): We achieved excellent and comparable pregnancy and live birth rates in poor responders of advanced reproductive age with the use of either GnRH antagonist or flare protocol. (Fertil Steril (R) 2010;93:360-3. (C)2010 by American Society for Reproductive Medicine.)